Neogen Chemicals Ltd. announced the outcome of its Board meeting held on February 11, 2026. The Board approved the Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. Critically, the Board also granted in-principle approval to raise up to ₹150 crore through a preferential issue of equity shares to the Promoter Group, subject to necessary regulatory sanctions. Furthermore, the Nomination and Remuneration Committee (NRC) approved the grant of 50,200 Stock Options.
Board Meeting Outcome: February 11, 2026
The Board of Directors of Neogen Chemicals Limited convened on Wednesday, February 11, 2026, from 2:30 p.m. to 7:30 p.m., approving several key resolutions concerning financial results and capital structure adjustments.
Q3 2025 Financial Results Approved
The Board approved the Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025, along with the corresponding Limited Review Report from the Statutory Auditors.
Standalone Highlights (Q3 FY26 vs Q3 FY25)
- Revenue from operations for the quarter stood at ₹215.60 crore (vs. ₹200.41 crore previously).
- Profit for the period (after tax) for the quarter was ₹8.77 crore (vs. ₹14.41 crore previously).
- Net profit margin for the quarter was 4% (vs. 5% previously).
Consolidated Highlights (Q3 FY26 vs Q3 FY25)
- Revenue from operations for the quarter stood at ₹220.02 crore (vs. ₹201.43 crore previously).
- Profit for the period (after tax) for the quarter was ₹3.69 crore (vs. ₹10.01 crore previously).
- Net profit margin for the quarter was 2% (vs. 3% previously).
The results also detailed an Exceptional Item loss of ₹13.56 crore on a standalone basis and ₹14.08 crore on a consolidated basis related to the fire incident at the Dahej SEZ Plant.
In-Principle Approval for Fund Raise
The Board granted In-principle approval for raising funds by way of issuance of equity shares on a preferential issue basis to the Promoter Group. This is subject to all necessary regulatory approvals.
- Aggregate Amount: Up to ₹150 crore (inclusive of any premium determined by the Board).
- Regulation Basis: Pursuant to SEBI ICDR Regulations, 2018.
Employee Stock Option Scheme Update (NCL ESOP Scheme 2024)
The Nomination and Remuneration Committee (NRC) also met on February 11, 2026, and approved the following actions related to the NCL ESOP Scheme 2024:
- Grant Approval: Approved the grant of 50,200 Stock Options (Tranche-II Grant) convertible into Equity Shares to 55 Eligible Employees.
- Vesting Approval: Approved the vesting of 4,650 employee stock options effective from April 1, 2026, relating to the Tranche-I Grant issued on April 1, 2025.
Security Coverage Certification for NCDs
The independent auditors provided a certificate confirming compliance with debt covenants as of December 31, 2025, regarding the ₹200 crore NCDs listed on the BSE. The auditors confirmed that the book value of assets accurately reflected the required security cover percentage, and covenants were complied with prima facie.
The Security Coverage Ratio (SCR) for the ₹200 Crore NCDs stood at 1.90 times as of December 31, 2025 (Standalone basis).
Source: BSE
